Predicting the Risks of Aggressive-Intent Chemotherapy Toxicity in Older Patients With Lymphoma: A Prospective Observational Pilot Study

• Published in: Clinical lymphoma, myeloma and leukemia myeloma and leukemia, 2022-08, Vol.22 (8), p.e792-e803
• Main Authors: Dhir, Vinita, Maganti, Manjula, Rozenberg, Dmitry, Kukreti, Vishal, Kuruvilla, John, Crump, Michael, Prica, Anca
• Format: Article
• Language: English
• Subjects: Aged; Aged, 80 and over; Aging; Cohort Studies; Frailty; Geriatric Assessment - methods; Geriatric oncology; Humans; Lymphoma; Lymphoma - diagnosis; Lymphoma - drug therapy; Physical performance testing; Pilot Projects; Prospective Studies
• ISSN: 2152-2650; 2152-2669
• DOI: 10.1016/j.clml.2022.04.011

Lymphoma is a disease of older patients and while treatment is subtype specific, curative or aggressive intent combination chemotherapy is often recommended. However, there has been limited evidence on which to base treatment decisions for older adults. Our objectives were to assess the utility of risk stratification measures and serial functional tests in predicting chemotherapy toxicity and as well the feasibility of conducting these in older adults undergoing chemotherapy for lymphoproliferative disorders. This prospective cohort study recruited lymphoma patients 70 years or older planned for systemic chemotherapy. The Cancer and Aging Research Group (CARG) risk stratification tool and Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) were calculated at baseline. The Clinical Frailty Scale (CFS), Charlson Comorbidity Index score, grip strength and gait speed test, and toxicity events, were assessed at baseline and serially throughout treatment. Sarcopenia was calculated on CT scans at baseline, midway through treatment, and 1-month after completion of therapy. The primary endpoint was to assess the feasibility of applying these measures in busy ambulatory clinics. These measures were also correlated with clinical outcomes including ≥grade 3 adverse events (AEs), hospitalizations and emergency department visits, dose changes or delays, and overall survival. In total, 30 patients were enrolled (mean age 78.1 ± 6.4 years), of whom 20 were treated with curative intent. A total of 16 patients (53%) experienced grade ≥3 AEs, 9 (56%) of which led to a chemotherapy delay. On univariable analyses, CFS score, a high CARG score, medium to high CRASH score, and the gait speed were associated with grade ≥3 AEs, while only CFS remained significant on multivariable analysis. On univariable analysis, patients with a medium to high risk CRASH score were more likely than low risk patients to have an unplanned emergency department visit or hospitalization. The CFS seems to predict toxicity in this cohort study, with gait speed, CARG and CRASH scores being potentially additional predictive methods of evaluation. In this prospective cohort study, thirty patients 70 years or older with lymphoma were recruited to assess the feasibility of different tests and models to predict chemotherapy-related adverse events. The results suggest the Clinical Frailty Scale shows promising utility, and this relatively easy test can be administered in an outpatient clinic to he